BVS
Bioventus Inc - Class A (BVS)
Healthcare • NASDAQ • $9.50+2.26%
- Symbol
- BVS
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Medical Devices
- Price
- $9.50
- Daily Change
- +2.26%
- Market Cap
- $590.09M
- Trailing P/E
- 21.24
- Forward P/E
- 9.61
- 52W High
- $11.25
- 52W Low
- $5.81
- Analyst Target
- $14.80
- Dividend Yield
- N/A
- Beta
- 0.67
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultr…
Company websiteResearch BVS on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.